Dsm Capital Partners LLC Regeneron Pharmaceuticals, Inc. Transaction History

Dsm Capital Partners LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$299.6 - $414.82 $112 Million - $155 Million	-374,203 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$372.08 - $439.57 $1.05 Million - $1.24 Million	2,823 Added 0.76%	374,203 $154 Million
Q4 2018 Feb 14, 2019	BUY	$335.82 - $403.04 $16.9 Million - $20.3 Million	50,410 Added 15.71%	371,380 $139 Million
Q3 2018 Nov 13, 2018	BUY	$351.14 - $408.51 $29.2 Million - $34 Million	83,276 Added 35.03%	320,970 $130 Million
Q2 2018 Aug 14, 2018	SELL	$284.6 - $344.99 $13.6 Million - $16.5 Million	-47,692 Reduced 16.71%	237,694 $82 Million
Q1 2018 May 14, 2018	SELL	$315.82 - $393.78 $268 Million - $335 Million	-849,954 Reduced 74.86%	285,386 $98.3 Million
Q4 2017 Feb 14, 2018	BUY	$358.63 - $469.95 $26.5 Million - $34.7 Million	73,889 Added 6.96%	1,135,340 $427 Million
Q3 2017 Nov 13, 2017	SELL	$431.38 - $504.0 $9.34 Million - $10.9 Million	-21,642 Reduced 2.0%	1,061,451 $475 Million
Q2 2017 Aug 14, 2017	BUY	N/A	1,083,093	1,083,093 $532 Million

1,534

83.6M

1.22M

1.51M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $75.2B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Dsm Capital Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Dsm Capital Partners LLC with notifications on news.